Showing posts with label Mupirocin Resistance. Show all posts
Showing posts with label Mupirocin Resistance. Show all posts

Saturday, October 17, 2009

Genetic Analysis of High-Level Mupirocin Resistance in ST80 clone of Community-Associated Methicillin-Resistant Staphylococcus aureus.

Genetic Analysis of High-Level Mupirocin Resistance in ST80 clone of
Community-Associated Methicillin-Resistant Staphylococcus aureus.

J Med Microbiol. 2009 Oct 15

Kuwait University.

Four Community- associated MRSA isolates expressing high-level mupirocin resistance (MIC: greater then1024mg/L) were isolated from four sites of a diabetic patient and characterized for the genetic location of their resistance determinants and typed using pulsed-field gel electrophoresis (PFGE), SCCmec coagulase gene and multilocus sequence typing to ascertain their relatedness. The presence of genes for resistance to high-level mupirocin (mupA), tetracycline (tetK) and fusidic acid (far 1), Panton-Valentine leukocidin (PVL), accessory gene regulators (agr) and capsular polysaccharide (cap) were detected in PCR assays. They were resistant to kanamycin, streptomycin, tetracycline, fusidic acid and cadmium acetate. They harboured mupA, tetK, far1, PVL, agr 3 and cap8.

They had identical PFGE pattern, coagulase gene type, possessed type IV SCCmec element and belonged to sequence type 80 (ST80). In contrast, they had three different plasmid profiles consisting of (1) 28.0 and 26.0 kb, (2) 28.0, 21.0 and 4.0 kb, (3). 41.0 and 4.0 kb. Genetic studies located resistance to tetracycline, fusidic acid and cadmium acetate on the 28 kb plasmids and mupA on related non conjugative 26 kb and 21 kb plasmids. One of the 21-kb mupirocin resistance plasmids was derived from the 41 kb plasmid during transfer experiments. The emergence of high-level mupirocin resistance in ST80-SCCmec-IV MRSA clone demonstrates the increasing capacity of CA-MRSA clones to acquire resistance to multiple antibacterial agents.

The presence of different plasmid profiles in genetically identical isolates created difficulty in interpretation of typing results and highlighted the weakness of using plasmid analysis as a sole method for strain typing.

PMID: 19833783 [PubMed - as supplied by publisher]

Monday, June 8, 2009

Topical Therapy for Methicillin-Resistant Staphylococcus aureus Colonization: Impact on Infection Risk.

Topical Therapy for Methicillin-Resistant Staphylococcus aureus Colonization: Impact on Infection Risk.

Infect Control Hosp Epidemiol. 2009 Jun

Robicsek A, Beaumont JL, Thomson Jr RB, Govindarajan G, Peterson LR.
From the Departments of Medicine (A.R.) and Pathology (R.B.T., L.R.P.), Feinberg School of Medicine, Northwestern University, Chicago, and the Department of Medicine (G.G.), the Division of Infectious Diseases (A.R.), the Division of Microbiology (R.B.T., L.R.P.), and the Center on Outcomes, Research, and Education (J.L.B.), NorthShore University HealthSystem, Evanston, Illinois.

Objective.

We evaluated the usefulness of topical decolonization therapy for reducing the risk of methicillin-resistant Staphylococcus aureus (MRSA) infection among MRSA-colonized inpatients.

Design.

Retrospective cohort study. Setting and intervention. Three hospitals with universal surveillance for MRSA; at their physician's discretion, colonized patients could be treated with a 5-day course of nasal mupirocin calcium 2%, twice daily, plus chlorhexidine gluconate 4% every second day. Patients and methods. MRSA carriers were later retested for colonization (407 subjects; study 1) or followed up for development of MRSA infection (933 subjects; study 2). Multivariable methods were used to determine the impact of decolonization therapy on the risks of sustained colonization (in study 1) and MRSA infection (in study 2).

Results.

Independent risk factors for sustained colonization included residence in a long-term care facility (odds ratio [OR], 1.8 [95% confidence interval {CI}, 1.1-3.2]) and a pressure ulcer (OR, 2.3 [95% CI, 1.2-4.4]). Mupirocin at any dose decreased this risk, particularly during the 30-60-day period after therapy; mupirocin resistance increased this risk (OR, 4.1 [95% CI, 1.6-10.7]). Over a median follow-up duration of 269 days, 69 (7.4%) of 933 patients developed infection. Independent risk factors for infection were length of stay (hazard ratio [HR], 1.2 per 5 additional days [95% CI, 1.0-1.4]), chronic lung disease (HR, 1.7 [95% CI, 1.0-2.8]), and receipt of non-MRSA-active systemic antimicrobial agents (HR, 1.8 [95% CI, 1.1-3.1]). Receipt of mupirocin did not affect the risk of infection, although there was a trend toward delayed infection among patients receiving mupirocin (median time to infection, 50 vs 15.5 days; [Formula: see text]).

Conclusions.

Mupirocin-based decolonization therapy temporarily reduced the risk of continued colonization but did not decrease the risk of subsequent infection.

ChicagoJournals

Thursday, March 27, 2008

The Emergence of Mupirocin Resistance among Clinical Isolates of Methicillin-Resistant Staphylococcus aureus in Trinidad: a First Report.

The Emergence of Mupirocin Resistance among Clinical Isolates of Methicillin-Resistant Staphylococcus aureus in Trinidad: a First Report.

Jpn J Infect Dis. 2008 Mar

Orrett FA.
Unit of Pathology and Microbiology, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago, West Indies.
drfao4301@yahoo.com.

The objective of the study was to investigate the trend of mupirocin resistance among methicillin-resistant Staphylococcus aureus (MRSA) in Trinidad. No premarketing susceptibility surveillance was ever done following the introduction of mupirocin in 1986. A total of 188 MRSA strains recovered over a 2-year period from various body sites were tested for mupirocin resistance via the disc diffusion method. The major sources of MRSA were surgical site infections (74.0%) and bloodstream infections (8.0%). High-level and low-level mupirocin resistance were detected in 26.1 and 44.1% of MRSA stains, respectively. Resistances to other non-beta-lactam antibiotics were also high. Ninety-eight percent of all MRSA were resistant to erythromycin. This was followed by resistance rates of 96.8, 95.2, 94.1, 93.6, and 93.1%, for gentamicin, ciprofloxacin, amikacin and tobramycin, co-trimoxazole, and tetracycline, respectively. No MRSA strains were found to be resistant to vancomycin, linezolid, and quinupristin-dalfopristin. The study showed that mupirocin resistance among Trinidadian MRSA strains was relatively high compared to that seen in other countries. Because of the increasing prevalence of MRSA at the San Fernando General Hospital (SFGH) and the apparently increasing resistance to mupirocin, frequent monitoring of MRSA susceptibility patterns and infection control initiatives may be helpful in reducing the incidence of MRSA with a concomitant decrease in mupirocin resistance. This report is the first after 20 years of continuous use of the drug at the SFGH.

Japanese Journal of Infectious Disease